Everyday Health on MSN
GLP-1 diabetes drug Mounjaro gets FDA okay to reduce heart attack and stroke
Research shows this tirzepatide GLP-1/GIP medication may help prevent cardiovascular emergencies in high-risk type 2 diabetes ...
With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...
In the world of weight loss medications, glucagon-like peptide-1 (GLP-1) receptor agonists have taken center stage. Research ...
An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory ...
NEW ORLEANS, June 5, 2026 /PRNewswire/ -- A new study evaluating the role of acmopatide (CT-868), a once-daily dual glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonist (GLP-1/GIP ...
Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options ...
Eli Lilly (LLY-2.81%) is one of the undisputed leaders in the GLP-1 market. The company's tirzepatide, sold under the brand ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces once-daily oral small molecule GLP-1 (ASC30) has received Phase III clearance from the U.S. Food and Drug Administration (FDA). ASC30 is the ...
Learn how GLP-1 medications affect nutrition and digestion, and discover six supplements that may help support protein intake ...
Eli Lilly's Zepbound mimics the action of the GLP-1 and GIP hormones. Its ability to combine these two mechanisms is a key reason why it has proven more effective for weight loss than Wegovy in ...
The drugs can sometimes cost more than $1,000 per month out of pocket.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results